Drug
Glucagon-Like Peptide 1
Glucagon-Like Peptide 1 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph not_applicable
2
50%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (33.3%)
N/A2 (66.7%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
Acute Effects of GLP-1 on Renal Hemodynamics
NCT04337268
completedphase_1
The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure
NCT02129179
completed
The Differential Effects of Diabetes Therapy on Inflammation
NCT02150707
completednot_applicable
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
NCT01413542
Clinical Trials (4)
Showing 4 of 4 trials
NCT04337268Not Applicable
Acute Effects of GLP-1 on Renal Hemodynamics
NCT02129179Phase 1
The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure
NCT02150707
The Differential Effects of Diabetes Therapy on Inflammation
NCT01413542Not Applicable
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4